百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06160 百济神州

未开盘 12-15 16:08:35

178.800

-15.700

-8.07%

最高191.000	最低178.000	成交量807.61万
今开191.000	昨收194.500	日振幅6.68%
总市值2,755亿	流通市值2,550亿	总股本15.41亿
成交额14.72亿	换手率0.57%	流通股本14.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":178.8,"timestamp":1765786115008,"preClose":194.5,"halted":0,"volume":8076098,"delay":0,"floatShares":1426000000,"shares":1541000000,"eps":-3.666147835696609,"marketStatus":"未开盘","change":-15.7,"latestTime":"12-15 16:08:35","open":191,"high":191,"low":178,"amount":1471836340,"amplitude":0.066838,"askPrice":178.9,"askSize":14400,"bidPrice":178.8,"bidSize":8100,"shortable":3,"etf":0,"ttmEps":0.35003969056920947,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":0,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":194.5,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"volumeRatio":2.242959,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":270.54,"timestamp":1765782000000,"preClose":276.5,"halted":0,"volume":2260300,"delay":0,"premium":"-40.18"}},"requestUrl":"/m/hq/s/06160/tweets","defaultTab":"tweets","newsList":[{"id":"2591697904","title":"午后突发！港股通创新药ETF（520880）跌2.77%创阶段新低，康方生物、百济神州等大权重龙头领跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2591697904","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591697904?lang=zh_cn&edition=full","pubTime":"2025-12-15 13:39","pubTimestamp":1765777140,"startTime":"0","endTime":"0","summary":"12月15日午后，港股通创新药板块加速下跌，港股通创新药ETF一度跌至2.77%创近5个月新低，龙头股齐挫，康方生物跌超5%，百济神州跌逾6%，中国生物制药、信达生物跌超3%。　　阶段新低之际，“抄底”资金或再行动，港股通创新药ETF场内宽幅溢价，显示买盘资金相对强势。　　把握港股创新药低吸窗口期，认准同类最大港股通创新药ETF及其场外联接基金，标的指数恒生港股通创新药精选指数具备三大独特优势：","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-15/doc-inhawauf3976382.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0348735423.USD","LU1961090484.USD","LU2476274308.USD","LU1720050803.USD","LU0540923850.HKD","LU2476274720.SGD","LU0634319403.HKD","LU1251922891.USD","IE00B5MMRT66.SGD","LU1770034418.SGD","LU2488822045.USD","LU0348825331.USD","09926","BK1500","BK1583","520880","LU2399975544.HKD","ONC","LU0348766576.USD","IE00B543WZ88.USD","BK1161","LU1303224171.USD","LU0348784397.USD","LU0588546209.SGD","LU1794554557.SGD","LU2778985437.USD","LU0417516738.SGD","LU0417516902.SGD","BK4585","LU0417516571.SGD","LU0307460666.USD","IE00BPRC5H50.USD","LU0348783233.USD","BK4526","06160","BK1574","BK4139","LU0348827113.USD","688235","BK0239","LU1969619763.USD","LU0561508036.HKD","LU0348767384.USD","LU1719994722.HKD","LU2328871848.SGD","BK1588"],"gpt_icon":0},{"id":"2591691376","title":"恒生医疗保健指数跌幅扩大至2.75% 医药股普遍走低 科伦博泰生物(06990)跌超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591691376","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591691376?lang=zh_cn&edition=full","pubTime":"2025-12-15 11:11","pubTimestamp":1765768311,"startTime":"0","endTime":"0","summary":"金吾财讯 | 恒生医疗保健指数跌幅扩大至2.75%，医药股普遍走低，科伦博泰生物(06990)跌7.07%，百济神州(06160)跌5.35%，复宏汉霖(02696)跌5.32%，荣昌生物(09995)跌4.05%，康方生物(09926)跌3.61%。","market":"hk","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU1961090484.USD","LU2488822045.USD","BK1161","LU2778985437.USD","LU1303224171.USD","LU2476274308.USD","LU0588546209.SGD","LU2476274720.SGD","LU0417516571.SGD","LU2399975544.HKD","LU0348767384.USD","LU1794554557.SGD","06160","LU0561508036.HKD","159506","LU0417516738.SGD","LU0348825331.USD","BK1500","BK1583","LU0634319403.HKD","LU2328871848.SGD","IE00BPRC5H50.USD","LU0348735423.USD","LU1720050803.USD","LU1770034418.SGD","IE00B5MMRT66.SGD","09926","LU1251922891.USD","IE00B543WZ88.USD","159938","09939","BK1574","LU0307460666.USD","06990","02696","BK1515","LU0348783233.USD","LU1719994722.HKD","HK0000165453.HKD","09995","LU0348766576.USD","LU0417516902.SGD","BK1588","LU0540923850.HKD","LU0348784397.USD","LU1969619763.USD","LU0196878994.USD"],"gpt_icon":0},{"id":"2591640278","title":"医药行业周报：医药板块逐步筑底","url":"https://stock-news.laohu8.com/highlight/detail?id=2591640278","media":"西南证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591640278?lang=zh_cn&edition=full","pubTime":"2025-12-15 10:06","pubTimestamp":1765764387,"startTime":"0","endTime":"0","summary":"投资要点行情回顾：本周医药生物指数下跌1.04%，跑输沪深300指数0.96个百分点，行业涨跌幅排名第18。中央经济工作会议12月10日至11日在北京举行，首次明确提出优化药品集中采购，深化医保支付方式改革。药品在原集采最低价中标基础上优化，叠加药品支付端改善，医药商业化空间或将进一步扩大。本次集采共纳入55种药品，中标率57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215100647a6a30153&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215100647a6a30153&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1303224171.USD","BK1583","06160","LU0588546209.SGD","LU1719994722.HKD","09939","BK1500","LU1969619763.USD","LU0307460666.USD","LU2328871848.SGD","LU1251922891.USD","LU1770034418.SGD","BK1515","BK1161","BK1574","BK1588"],"gpt_icon":0},{"id":"2591015695","title":"千亿市值创新药企俱乐部扩容！百济神州、百利天恒、信达生物等强势崛起","url":"https://stock-news.laohu8.com/highlight/detail?id=2591015695","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591015695?lang=zh_cn&edition=full","pubTime":"2025-12-15 09:51","pubTimestamp":1765763499,"startTime":"0","endTime":"0","summary":"根据数据统计，截至11月19日，A股和港股的千亿市值创新药企俱乐部已扩容至8家。其中，百济神州A股总市值超过4000亿元，百利天恒总市值超过1500亿元。港股千亿市值俱乐部包括百济神州、翰森制药、信达生物、康方生物等。其中，总市值超4000亿元的创新药企业百济神州已连续两个季度实现盈利。据悉，在研发方面，百济神州的研发管线也进入集中兑现阶段，未来18个月将迎来20项关键里程碑事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215095603a44bddeb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215095603a44bddeb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1589","HK0000165453.HKD","LU2097828805.USD","LU1969619763.USD","LU2097828714.EUR","BK1583","LU1719994722.HKD","LU2488822045.USD","91194","LU2097828474.EUR","LU0307460666.USD","LU2328871848.SGD","LU1770034418.SGD","03692","BK1574","LU0455707207.USD","06160","06978","BK1500","LU1251922891.USD","LU2097828631.EUR","LU0502904849.HKD","LU2242644610.SGD","BK1588","01801","LU1303224171.USD","LU0588546209.SGD","LU2097828557.USD","02615"],"gpt_icon":0},{"id":"2591660345","title":"智通港股通资金流向统计(T+2)|12月15日","url":"https://stock-news.laohu8.com/highlight/detail?id=2591660345","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591660345?lang=zh_cn&edition=full","pubTime":"2025-12-15 07:31","pubTimestamp":1765755061,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，12月10日,招商银行、小米集团-W、农业银行南向资金净流入金额位列市场前三，分别净流入6.88 亿、6.17 亿、3.46 亿盈富基金、腾讯控股、恒生中国企业南向资金净流出金额位列市场前三，分别净流出-15.57 亿、-6.08 亿、-4.78 亿在净流入比方面，工银南方中国、新华文轩、深圳高速公路股份以100.00%、75.27%、72.14%位列市场前三。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02666","01288","00636","00811","03968","06886","01088","HKXCY","03618","00934","00288","00388","01810","03167","00857","HYDD.SI","00966","002594","01789","06160","01053","HTCD.SI","XIACY","02828","00883","02378","01361","00548","01310","00425","HEXmain","00220","00700","02800","89988","06818","02218","02423","03033","81211","BYDDY","03668","HBBD.SI","00270"],"gpt_icon":1},{"id":"2591663796","title":"医疗与消费周报：创新药行业研发突破与市场演进的并行","url":"https://stock-news.laohu8.com/highlight/detail?id=2591663796","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591663796?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:08","pubTimestamp":1765699711,"startTime":"0","endTime":"0","summary":"投资要点：近期观点1、医药指数本周关注的6个子行业只有一个录得正收益。新药分为强调全新结构的1类（创新药）与强调临床优势的2类。近年来产业规模持续扩大，从2020年约8198亿元增至2024年1.14万亿元，年均复合增长率达8.53%，预计2025年将达1.22万亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214160834a44985a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214160834a44985a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01276","LU0588546209.SGD","BK1574","LU1719994722.HKD","LU1969619763.USD","02359","BK1583","06978","06160","BK1500","LU2328871848.SGD","LU1303224171.USD","BK1588","LU0307460666.USD","LU1251922891.USD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2591663797","title":"百济神州发布A股关联交易管理制度 规范内部治理","url":"https://stock-news.laohu8.com/highlight/detail?id=2591663797","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591663797?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:12","pubTimestamp":1765671153,"startTime":"0","endTime":"0","summary":"中访网数据  百济神州有限公司于近日正式发布《A股关联交易管理制度》，旨在进一步规范公司关联交易行为，完善内部治理结构，以符合上海证券交易所科创板上市规则及相关法律法规的要求。该制度明确了关联方与关联交易的定义、审议程序及基本原则。在审议程序上，公司将严格依照其既定的《关联交易政策》和《关连交易管理政策》中规定的决策权限和流程执行，确保交易合规。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214082426a44876ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214082426a44876ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0307460666.USD","LU1969619763.USD","LU2328871848.SGD","BK1500","LU1719994722.HKD","LU0588546209.SGD","06160","LU1251922891.USD","BK1583","LU1303224171.USD","BK1588","LU1770034418.SGD"],"gpt_icon":0},{"id":"2591794663","title":"百济神州发布内部审计章程，强化公司治理与风险管控","url":"https://stock-news.laohu8.com/highlight/detail?id=2591794663","media":"中访网数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591794663?lang=zh_cn&edition=full","pubTime":"2025-12-14 08:12","pubTimestamp":1765671149,"startTime":"0","endTime":"0","summary":"中访网数据  百济神州有限公司近日正式发布其内部审计章程，明确了内部审计职能的核心目标与运作框架。核心决策方面，章程确立了内部审计直接向公司审计委员会汇报的职能关系，确保了其组织独立性与权威性。首席审计师在职能上向审计委员会报告，日常行政事务由首席财务官指导，这种架构旨在保障内部审计工作的客观性不受干扰。审计委员会被授权审批内部审计章程、年度审计计划与预算，并负责首席审计师的任免与业绩评估。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214082406a69f8de2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214082406a69f8de2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1500","LU1719994722.HKD","BK1161","06160","LU1969619763.USD","BK1583","BK1588","LU0307460666.USD","LU2328871848.SGD","LU1770034418.SGD","LU0588546209.SGD","LU1251922891.USD","LU1303224171.USD"],"gpt_icon":0},{"id":"2591657917","title":"医药行业周报：IN VIVO CART：BD热门赛道 早期技术具备广阔前景","url":"https://stock-news.laohu8.com/highlight/detail?id=2591657917","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591657917?lang=zh_cn&edition=full","pubTime":"2025-12-14 00:00","pubTimestamp":1765641600,"startTime":"0","endTime":"0","summary":"核心观点：In Vivo CART赛道发展火热，2025年已经有四个MNC并购的案例发生。具体来看，In Vivo CART分为LNP和慢病毒两条技术路线，两条技术路线均具备显著特色。LNP路线来看，药物在临床前展现出了快速转染以及优异的靶向性特点，慢病毒路线中，Esobiotec等公司的BCMA In Vivo CART已经在小人群MM患者中展现非常好的早期数据。整体看，In VivoCART发展迅速，后续发展值得关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214150229a4496027&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214150229a4496027&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","LU2242644610.SGD","06821","LU0052750758.USD","06160","LU0708995583.HKD","BK1141","LU0320764599.SGD","02359","01801","LU2125910500.SGD","BK1583","BK1574","LU2045819591.USD","01177","BK1576","LU1046422090.SGD","BK1161"],"gpt_icon":0},{"id":"2591657861","title":"医药生物行业周报：2025国谈结果公布 关注相关公司投资机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2591657861","media":"开源证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591657861?lang=zh_cn&edition=full","pubTime":"2025-12-14 00:00","pubTimestamp":1765641600,"startTime":"0","endTime":"0","summary":"2025 国谈结果重磅公布，关注相关公司投资机会12 月7 日，国家医保局重磅发布2025 年医保谈判结果，此外还首次同步启动了商保目录的制定工作。2025 医保目录新增114 种药品，总体成功率达88%，谈判成功率创近7 年新高，最高降幅94%，新版目录自2026 年1 月1 日起正式执行。12 月第2 周医药生物下跌1.04%，医疗研发外包板块涨幅最大从月度数据来看，2025 年初至今沪深整体呈现上行趋势。本周医药生物下跌1.04%，跑输沪深300 指数0.96pct，在31 个子行业中排名第17 位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214143634a4495150&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214143634a4495150&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01801","03933","06160","06978","01167","BK1161"],"gpt_icon":0},{"id":"2590233595","title":"【券商聚焦】交银国际：创新药增量支付空间持续扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2590233595","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590233595?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:02","pubTimestamp":1765501348,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，10月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓整体平稳，内外资加大创新药布局的大方向不变。该机构指，本周医保+商保双目录落地，医保谈判新增品种成功率创近年新高，续约品种降价幅度相对温和。该机构认为商保资金的引入将为创新药支付带来重要增量资金，进一步优化多元支付体系。该机构看好医保新纳入品种/适应症在2026年的销售放量，以及首版商保目录的实际执行和支付情况。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971425","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","159992","LU1951186391.HKD","LU0043850808.USD","LU2778985437.USD","HK0000165453.HKD","LU0181495838.USD","LU0516423091.SGD","LU0067412154.USD","LU2097828557.USD","LU0502904849.HKD","LU1226287529.USD","LU0359201612.USD","LU0634319403.HKD","LU1961090484.USD","01801","02142","LU0708995583.HKD","02616","LU0417516738.SGD","BK1161","01877","LU0359202008.SGD","09995","02269","LU1993786604.SGD","LU1969619763.USD","SG9999004220.SGD","01093","LU0540923850.HKD","LU0880133367.SGD","LU2039709279.SGD","BK1588","LU1770034418.SGD","06160","LU0348766576.USD","01177","06185","LU2097828714.EUR","03329","09688","LU2097828631.EUR","LU0456827905.SGD","LU2242644610.SGD","09926","LU2328871848.SGD","IE00B0JY6N72.USD","LU1794554557.SGD","06978","LU1242518931.SGD"],"gpt_icon":0},{"id":"2590454256","title":"重磅！圣湘牵手万亿大药企！","url":"https://stock-news.laohu8.com/highlight/detail?id=2590454256","media":"IVD从业者网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590454256?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:56","pubTimestamp":1765457787,"startTime":"0","endTime":"0","summary":"此次携手，双方将以圣湘海济为重要锚点，实现其生物制药平台能力与百济神州顶尖创新研发实力的强强联合，为圣湘诊疗一体化能力建设装上强劲引擎，驱动精准诊疗全链业务加速驶入创新突破与产业腾飞的“快车道”。圣湘生物与百济神州现场签约随后，百济神州生物岛创新中心首席执行官刘建博士与圣湘生物执行总经理彭铸分别代表双方签署合作协议，标志着本次“诊疗一体化”深度合作全面启动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211224339a442b3ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211224339a442b3ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","LU0588546209.SGD","LU1969619763.USD","LU1719994722.HKD","BK1583","06160","BK1500","LU2328871848.SGD","LU1303224171.USD","BK1588","LU0307460666.USD","LU1251922891.USD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2590568001","title":"创新药热潮与商业化红利共振 BD交易额破1200亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590568001","media":"金证研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590568001?lang=zh_cn&edition=full","pubTime":"2025-12-11 08:42","pubTimestamp":1765413720,"startTime":"0","endTime":"0","summary":"跨国药企面临严峻的专利悬崖问题，中国创新药作为其管线补充的重要来源之一，在2025年迎来BD爆发元年，交易数据持续攀升。10月创新药BD交易仍然频繁，交易总额达200亿美元，截止10月底，2025年的BD累计交易总额已超过1200亿美元，同比增长190%，这表明BD交易已从偶发事件逐渐转变为行业常态。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512110843099536967a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512110843099536967a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","06978","01877","BK1161","BK1574","BK1583","BK1515","01801"],"gpt_icon":0},{"id":"2590537045","title":"刚刚！圣湘签约顶级药企...","url":"https://stock-news.laohu8.com/highlight/detail?id=2590537045","media":"IVD经销商","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590537045?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:22","pubTimestamp":1765372928,"startTime":"0","endTime":"0","summary":"此次携手，双方将以圣湘海济为重要锚点，实现其生物制药平台能力与百济神州顶尖创新研发实力的强强联合，为圣湘诊疗一体化能力建设装上强劲引擎，驱动精准诊疗全链业务加速驶入创新突破与产业腾飞的“快车道”。圣湘生物与百济神州现场签约随后，百济神州生物岛创新中心首席执行官刘建博士与圣湘生物执行总经理彭铸分别代表双方签署合作协议，标志着本次“诊疗一体化”深度合作全面启动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210220147a72ff19e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210220147a72ff19e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","BK1588","BK1500","06160","LU1251922891.USD","LU1719994722.HKD","LU2328871848.SGD","LU0588546209.SGD","BK1161","LU1969619763.USD","BK1583","LU1303224171.USD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2590537028","title":"“诊疗一体化”加速 圣湘生物与百济神州生物岛创新中心达成合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2590537028","media":"e公司","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590537028?lang=zh_cn&edition=full","pubTime":"2025-12-10 18:28","pubTimestamp":1765362480,"startTime":"0","endTime":"0","summary":"日前，圣湘生物科技股份有限公司与百济神州（广州）创新科技有限公司在北京正式签署战略合作协议。通过在精准健康领域的多年深耕，圣湘生物目前已全面启动诊疗一体化生态建设，其中圣湘海济是圣湘在生物制药领域的核心载体。作为此次合作的落地载体，百济神州生物岛创新中心将依托已有的科研配套、临床资源与产业孵化能力，成为双方协同的核心枢纽。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210183125a43fe23e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210183125a43fe23e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1303224171.USD","BK1500","BK1588","LU0588546209.SGD","LU1969619763.USD","BK1161","LU2328871848.SGD","LU1719994722.HKD","LU1770034418.SGD","LU0307460666.USD","LU1251922891.USD","BK1583","06160"],"gpt_icon":1},{"id":"2590370375","title":"每日卖空追踪 | 百济神州 12月10日卖空量成交23.47万股，卖空比例为6.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590370375","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590370375?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:30","pubTimestamp":1765355436,"startTime":"0","endTime":"0","summary":"百济神州北京时间12月10日，跌1.15%，卖空量成交23.47万股，较上一交易日减少74.91%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210163817a72f50cd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251210163817a72f50cd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","LU1303224171.USD","06160","LU1719994722.HKD","BK1588","LU1251922891.USD","BK1583","BK1500","LU1969619763.USD","LU1770034418.SGD","LU2328871848.SGD","LU0588546209.SGD","BK1161"],"gpt_icon":0},{"id":"2590303708","title":"重磅事件落地！商业化+出海提速，板块调整后弹性更突出","url":"https://stock-news.laohu8.com/highlight/detail?id=2590303708","media":"浙商证券融资融券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590303708?lang=zh_cn&edition=full","pubTime":"2025-12-10 13:02","pubTimestamp":1765342962,"startTime":"0","endTime":"0","summary":"关注研发实力强且已有商业化创新药产品上市的企业；CXO及生命科学上游产业链。CXO一体化龙头公司如药明康德，保持业绩持续向好趋势，业绩保持较快增长。投资者据此操作，风险自负。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512101335329534f1c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512101335329534f1c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","06160","06821","BK1141","BK1574","LU1046422090.SGD","LU2045819591.USD","06978","02268","LU0052750758.USD","03759","BK1576","LU2125910500.SGD","02359","LU2242644610.SGD","BK1161","LU0708995583.HKD","LU0320764599.SGD","01801"],"gpt_icon":0},{"id":"2590326325","title":"每日卖空追踪 | 百济神州 12月09日卖空量成交24.45万股，卖空比例为6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590326325","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590326325?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:30","pubTimestamp":1765269035,"startTime":"0","endTime":"0","summary":"百济神州北京时间12月09日，跌0.88%，卖空量成交24.45万股，较上一交易日减少64.9%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163548a43d40fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163548a43d40fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","LU1251922891.USD","LU1303224171.USD","LU1719994722.HKD","LU1770034418.SGD","LU1969619763.USD","BK1583","BK1588","BK1500","BK1161","LU0588546209.SGD","LU2328871848.SGD","06160"],"gpt_icon":0},{"id":"2590348233","title":"中信证券：医保谈判成功率创近年新高，关注创新药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348233","media":"瑞财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590348233?lang=zh_cn&edition=full","pubTime":"2025-12-09 14:57","pubTimestamp":1765263437,"startTime":"0","endTime":"0","summary":"瑞财经 严明会近日，中信证券指出，2025年12月7日，2025创新药高质量发展大会在广州举行，国家医保局现场发布了2025年《国家基本医疗保险、生育保险和工伤保险药品目录》及《商业健康保险创新药品目录》。在基本医保目录上，最终114个成功纳入，其中包含50个1类创新药，成功率为88%，谈判成功率创近7年新高。与此同时，首版商保目录发布，共纳入19款产品，包含5款CAR-T产品。中信证券认为，伴随着国家对创新药持续的政策倾斜和鼓励支持，医保和商保的双轨并行，有望带动支付多元化，创新药企的回报有望逐步提升。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512091457209532ed86&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512091457209532ed86&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","02359","06160","BK4526","BK4139","BK4585"],"gpt_icon":0},{"id":"2590348255","title":"药价登记，出海新支点","url":"https://stock-news.laohu8.com/highlight/detail?id=2590348255","media":"药视声Medispace","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590348255?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:58","pubTimestamp":1765252739,"startTime":"0","endTime":"0","summary":"本土龙头企业如恒瑞医药、百济神州等持续投入高额研发费用，其中恒瑞医药已在中国获批上市23款1类新分子实体创新药，覆盖肿瘤、自身免疫等领域。从早期的原料药出口，到现在的创新药License-out，2025年上半年国产创新药对外授权交易总金额已接近660亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209164810a43d48ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209164810a43d48ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","01276","BK4585","ONC","06160","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beonemedicines.com","stockEarnings":[{"period":"1week","weight":-0.0769},{"period":"1month","weight":-0.1813},{"period":"3month","weight":-0.0905},{"period":"6month","weight":0.1565},{"period":"1year","weight":0.6494},{"period":"ytd","weight":0.6374}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.0533},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0809},{"period":"1year","weight":0.2833},{"period":"ytd","weight":0.2776}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"BeOne Medicines AG（原名：BeiGene Ltd）是一家全球肿瘤学公司，致力于为全球癌症患者研发新疗法。该公司产品组合涵盖血液学和实体瘤，致力于开发多样化的新型疗法。其产品包Brukinsa、Tevimbra和Pamiparib。Brukinsa是一种口服的布鲁顿酪氨酸激酶(BTK)小分子抑制剂。Tevimbra是一种人源化免疫球蛋白G4（IgG4）抗程序性细胞死亡蛋白1（PD-1）单克隆抗体，具有高亲和力和对PD-1的结合特异性。Tevimbra旨在最大限度地减少与巨噬细胞上Fc-γ（Fcy）受体的结合，帮助人体免疫细胞检测和对抗肿瘤。该公司正在开发的产品线包括Sonrotoclax、Tarlatamab、Zanidatamab、Blinatumomab、BGB-26808、BGB-R046、BG-68501、BG-C9074、BGB-43395、Xaluritamig等。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.009815},{"month":2,"riseRate":0.571429,"avgChangeRate":0.046604},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.052519},{"month":4,"riseRate":0.428571,"avgChangeRate":0.037509},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.052709},{"month":6,"riseRate":0.428571,"avgChangeRate":0.007027},{"month":7,"riseRate":0.857143,"avgChangeRate":0.097108},{"month":8,"riseRate":0.857143,"avgChangeRate":0.058603},{"month":9,"riseRate":0.5,"avgChangeRate":0.025162},{"month":10,"riseRate":0.5,"avgChangeRate":-0.027038},{"month":11,"riseRate":0.625,"avgChangeRate":0.118183},{"month":12,"riseRate":0.125,"avgChangeRate":-0.076075}],"exchange":"SEHK","name":"百济神州","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,06160,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(06160)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(06160)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}